
AUA2025 featured a wide range of content that is now available to be viewed on-demand thanks to educational grant support.
Oncology – General
Bladder Cancer
Prostate Cancer
Overactive Bladder
Satellite Symposia
Oncology – General
Course 031IC: Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities
This educational activity is supported by independent educational grants from:
- Astellas
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
Course 042IC: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)
This educational activity is supported by independent educational grants from:
- Astellas
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
Course 046IC: Genetics and Genomics of Urological Cancers – Current Guidelines and Case-based Discussion to Guide Clinical Practice
This educational activity is supported by independent educational grants from:
- Astellas
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
Bladder Cancer
Course 062IC: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them
This educational activity is supported by an independent educational grant from:
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Course 047IC: Management of Non-Muscle Invasive Bladder Cancer: Practical Solutions for Common Problems
This educational activity is supported by an independent educational grant from:
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Satellite Symposium – Putting Precision Into Practice for Bladder Cancer Treatment Insights for Individualized Care Across the Disease Continuum
Live From AUA2025: Highlights in NMIBC
This educational activity is supported by independent educational grants from:
- ImmunityBio, Inc.
- Merck & Co., Inc.
Prostate Cancer
Course 017IC: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025
This educational activity is supported by independent educational grants from:
- Astellas
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
Course 051IC: AUA Guidelines on Early Detection of Prostate Cancer: Maximizing Benefits, Minimizing Harm
This educational activity is supported by independent educational grants from:
- Astellas
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
Course 057IC: Incorporating Genomic Testing and Advanced Imaging for Prostate Cancer Into Your Practice
This educational activity is supported by independent educational grants from:
- Astellas
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
Course 063IC: AUA Advanced Prostate Cancer Course
This educational activity is supported by independent educational grants from:
- Astellas
- Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
- Pfizer, Inc.
AUA2025 Forum: Integration of Biomarkers, MRI and PSMA PET
This educational activity is supported by independent educational grants from:
- Blue Earth Diagnostics, Inc.
- Lantheus Medical Imaging
- Novartis Pharmaceuticals Corporation
AUA2025 Spotlight: PARP-Inhibitor Combination Treatments for the Urologic Care Team
This educational activity is supported by independent educational grants from:
- AstraZeneca and Merck & Co., Inc.
Satellite Symposium – Personalizing Prostate Cancer Care Real-World Approaches for the Community Urology Practice
Satellite Symposium – DATA & PERSPECTIVES: Clinical Investigators Discuss the Emerging Role of AKT Inhibitors in the Care of Patients with Prostate Cancer
Live From AUA2025: Highlights in ADT
This educational activity is supported by independent educational grants from:
- Pfizer, Inc.
- Sumitomo Pharma America, Inc.
Overactive Bladder
Satellite Symposium – Next-Gen Solutions in Urology: Integrating Innovative Treatments for OAB and BPH into Practice
Satellite Symposia
Satellite Symposium – Personalizing Prostate Cancer Care Real-World Approaches for the Community Urology Practice
Satellite Symposium – Putting Precision Into Practice for Bladder Cancer Treatment Insights for Individualized Care Across the Disease Continuum
Satellite Symposium – DATA & PERSPECTIVES: Clinical Investigators Discuss the Emerging Role of AKT Inhibitors in the Care of Patients with Prostate Cancer
Satellite Symposium – Next-Gen Solutions in Urology: Integrating Innovative Treatments for OAB and BPH into Practice